|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Percutaneous biliary metal wall stenting in malignant obstructive jaundice显示文摘 | Adrian A Indar Dileep N Lobo Andrew D Gilliam Roger Gregson Ian Davidson Simon Whittaker John Doran Brian J Rowlands Ian J Beckingham | 2003 | European Journal of Gastroenterology & Hepatology2003，，： | 1 |
| 2 | Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett’s esophagus: a prospective, double-blinded study显示文摘 | Gerard Isenberg Michael V. Sivak Amitabh Chak Richard C.K. Wong Joseph E. Willis Brian Wolf Douglas Y. Rowland Ananya Das Andrew Rollins | 2005 | Gastrointestinal Endoscopy2005，，6： | 1 |
| 3 | Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours显示文摘 | Andrew Rowland Mafalda M. Dias Michael D. Wiese Ganessan Kichenadasse Ross A. McKinnon Christos S. Karapetis Michael J. Sorich | 2015 | European Journal of Cancer2015，，： | 1 |
| 4 | Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett’s esophagus: a prospective, double-blinded study显示文摘 | Gerard Isenberg Michael V. Sivak Amitabh Chak Richard C.K. Wong Joseph E. Willis Brian Wolf Douglas Y. Rowland Ananya Das Andrew Rollins | 2005 | Gastrointestinal Endoscopy2005，，6： | 1 |
| 5 | Novel Mutation in Desmoplakin Causes Arrhythmogenic Left Ventricular Cardiomyopathy显示文摘 | Mark Norman Michael Simpson Jens Mogensen Anthony Shaw S?an Hughes Petros Syrris Srijita Sen-Chowdhry Edward Rowland Andrew Crosby William J. McKenna | 2005 | Circulation2005，，5： | 1 |
| 6 | Candidate radial-inflow turbines and high-density working fluids for geothermal power systems显示文摘 | Emilie Sauret Andrew S. Rowlands | 2011 | Energy2011，，7： | 1 |
| 7 | Hepatitis C Transmission, Prevention, and Treatment Knowledge Among Patients with HIV显示文摘 | Rae Jean Proeschold-Bell Rachel Blouin Susan Reif Arit Amana Benjamin J. Rowland Frank Lombard Beth Stringfield Andrew J. Muir | 2010 | Southern Medical Journal2010，，7： | 1 |
| 8 | Fracture of allograft interbody spacer resulting in post-operative radiculopathy: A case report显示文摘BACKGROUND Allograft interbody spacers are utilized during transforaminal lumbar interbody fusion(TLIF) to reestablish anterior column support and disc height. While the TLIF technique offers many improvements over previous surgical methods,instrumentation and bone graft-related complications such as spacer misplacement or migration, screw fracture or misplacement, or rod breakage continue to be reported. The objective of this manuscript is to report on a fractured allograft interbody spacer that displaced into the neural foramen and resulted in impingement on the exiting nerve root that required revision.CASE SUMMARY A 50-year-old male had two-level TLIF with immediate post-operative right L5 radiculopathy. Computed tomography scan demonstrated a fractured allograft interbody spacer that displaced into the right neural foramen and impinged on the exiting L5 nerve root. Revision surgery was performed to remove the broken allograft fragments from the right L5 foramen and the intact portion of the spacer was left in place. The right leg L5 radicular pain resolved. At the last follow up 12 mo after the index procedure, computed tomography scan confirmed sound interbody and posterolateral fusion.CONCLUSION Displacement of broken allograft interbody spacer following TLIF procedures can result in neurological sequelae that require revision. To avoid such an occurrence,the authors recommend allowing sufficient time for the reconstitution of the graft in saline prior to use to decrease brittleness, to use an impactor size that is as close as possible to the spacer size and meticulous inspection of the cortical allograft spacer for any visible imperfection prior to insertion. | Andrews Kyle Andrea Rowland Jacob Stirton Hossein Elgafy | 2019 | World Journal of Orthopedics2019，10，4： | 0 |
| 9 | Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data显示文摘Objective: Several predictors of survival have been identified in EGFR-positive non-small cell lung cancer(NSCLC) patients treated with first generation EGFR inhibitors. Prognostic models of survival outcomes with afatinib have not been evaluated.Methods: A prognostic tool for overall survival(OS)/progression free survival(PFS) based on pre-treatment clinicopathological factors was developed for EGFR-positive advanced NSCLC patients treated with first-line afatinib using penalised regression of individual-participant data from LUX-Lung 3 and 6(n = 468). Favourable, intermediate and poor risk groups were identified and externally validated using LUX-Lung 1(n = 390) and LUX-Lung 2(n = 129) trials that initiated afatinib following previous chemotherapy or EGFR inhibitor treatment.Results: Discriminative performance was good in the development and validation cohorts. For patients treated with first-line afatinib, the median OS for the favourable, intermediate and poor risk groups were > 47.7, 29.3 and 16.4 months, respectively, and the median PFS were 17.3, 13.2 and 8.3 months, respectively. The improvement in median OS with afatinib use compared to chemotherapy was > 12.4 months for the favourable risk group, whereas no OS benefit was apparent for the poor risk group. The improvement in median PFS with afatinib use compared to chemotherapy was 10.2 months for the favourable risk group and 3.2 months for the poor risk group.Conclusions: A prognostic tool was developed and validated to identify favourable, intermediate and poor risk groups for OS/PFS in EGFR-positive advanced NSCLC patients treated with afatinib. The prognostic groups can inform the likely absolute OS/PFS benefit expected from afatinib compared to chemotherapy in first-line treatment. | Ashley M. Hopkins Adel Shahnam Sasha Zhang Chris S. Karapetis Andrew Rowland Michael J. Sorich | 2019 | Cancer Biology & Medicine2019，16，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员